Lung Cancer Europe shared a post on LinkedIn:
“When lung cancer is described as having spread, the specific word used carries real meaning.
Localised, locally advanced, metastatic, oligometastatic and polymetastatic are not interchangeable. These terms describe patterns of spread. They relate to lung cancer staging, but they are not stages themselves.
Each describes how far the cancer has spread, and each points to a different treatment goal. Getting them right is part of communicating about lung cancer accurately.
Localised means the cancer is still within the lung and has not spread elsewhere. It generally corresponds to the earliest stages of disease. Because it is contained, treatment is usually given with the aim of removing or destroying it completely, through surgery or targeted radiotherapy. This is the group most likely to be treated with curative intent.
Locally advanced means the cancer has extended into nearby tissues or reached lymph nodes close to the lung, without spreading to distant organs. It sits between localised and metastatic disease. Treatment is often still given with curative intent, typically combining chemotherapy, radiotherapy and sometimes surgery.
Worth noting: ‘advanced’ on its own is ambiguous in common use, covering both locally advanced and metastatic disease. Precision helps, so it is worth being clear which is meant.
Metastatic means the cancer has spread to distant parts of the body, beyond the lung and nearby lymph nodes. It is also called secondary cancer.
Oligometastatic describes limited distant spread, commonly one to five sites, though definitions vary. It is a meaningful distinction because limited spread can sometimes be treated intensively, with radiotherapy or surgery directed at those few sites alongside systemic treatment.
One point often lost: when lung cancer spreads, it remains lung cancer. Lung cancer in the brain is metastatic lung cancer, not brain cancer, and it is treated accordingly.
Polymetastatic means the cancer has spread more widely, to multiple sites. Here treatment is generally aimed at controlling the disease rather than removing it, using systemic treatments that act throughout the body, such as targeted therapies, immunotherapy or chemotherapy.
The distinction from oligometastatic is not academic. It often influences whether treatment is directed at specific sites or works across the whole body. With biomarker testing and newer treatments, many people now live well with metastatic lung cancer for a considerable time.
So why does the difference between these words count?
Because where the cancer has spread informs the goal of treatment, from curing localised disease to controlling more widespread disease while protecting quality of life.
For anyone communicating about lung cancer, using these terms precisely is part of representing the disease and the people living with it accurately. When the words are vague, the picture blurs. When they are clear, so is the conversation.”
Other articles from Lung Cancer Europe on OncoDaily.